Aurobindo Pharmashare: USFDA Inspection, VAI Status & Q1FY27 Profit Surge
NEWZA Editorial Team••Source: MoneyControl
NEWZAFinancial Intelligence Feed
⚡ Key Financial Takeaways
USFDA inspection of Telangana facility yielded only one maintenance observation, no GMP breach; corrective action underway.
Q1FY27 net profit rose 25.2% to ₹1,032 cr, revenue up 16.3% to ₹9,150.3 cr, EBITDA up 17.3% to ₹1,881 cr, margin 21%.
Raleigh, NC plant classified as ‘Voluntary Action Indicated’ (VAI) in the Establishment Inspection Report (EIR).
USFDA Inspection & Compliance The United States Food and Drug Administration conducted a routine inspection at Aurobindo Pharmashare’s Telangana facility (AuroPeptides) from 17‑21 Aug 2026. The audit concluded with a single observation related to facility and equipment maintenance, with no impact on data integrity or GMP compliance. The company has already initiated corrective action and will submit a formal response within the stipulated timeline.
Q1FY27 Financial Performance Aurobindo Pharmashare posted a 25.2% year‑on‑year rise in net profit to ₹1,032 cr for Q1FY27, surpassing the ₹824 cr reported a year earlier. Revenue climbed 16.3% YoY to ₹9,150.3 cr from ₹7,868 cr, beating the CNBC‑TV18 poll estimate of ₹9,030 cr. EBITDA increased 17.3% YoY to ₹1,881 cr, ahead of the ₹1,848 cr estimate, and the EBITDA margin improved to 21% from 20%.
Raleigh Plant VAI Status & Market Implications The company also received an Establishment Inspection Report (EIR) for its Raleigh, North Carolina plant, classifying it as “Voluntary Action Indicated” (VAI). This status signals that the facility requires attention but is not subject to immediate enforcement action. Investors and analysts will closely monitor the company’s response to the VAI to gauge potential regulatory impact on future earnings.
